MicroPort NeuroTech (2172) Fundamentals 2026 — P/E 23.7x, Revenue Analysis | SniperIQ
MicroPort NeuroTech (2172) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK$5.1B, trading at HK$8.81 on the HKSE. This SniperIQ fundamentals page covers MicroPort NeuroTech's valuation (P/E 23.7x, P/B 2.4x), profitability (net margin 23.3%), revenue (¥770M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MicroPort NeuroTech's market cap?
MicroPort NeuroTech (2172) has a market capitalization of approximately HK$5.1B, trading at HK$8.81 on the HKSE. Market cap moves with the live share price.
What is MicroPort NeuroTech's P/E ratio?
MicroPort NeuroTech's trailing twelve-month P/E ratio is 23.7x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MicroPort NeuroTech?
MicroPort NeuroTech runs a net profit margin of 23.3%, a gross margin of 73.5%, and an operating margin of 37.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MicroPort NeuroTech generate?
MicroPort NeuroTech reported revenue of ¥770M for fiscal year 2025, with net income of ¥180M and earnings per share (EPS) of 0.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MicroPort NeuroTech pay a dividend?
MicroPort NeuroTech offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is MicroPort NeuroTech financially healthy?
MicroPort NeuroTech carries a debt-to-equity ratio of 0.01x and a current ratio of 6.01x, with a market beta of -0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MicroPort NeuroTech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MicroPort NeuroTech (2172) the key facts are: market cap HK$5.1B, P/E 23.7x, revenue ¥770M, 52-week range 8.4-16.44. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MicroPort NeuroTech's full fundamentals live
Get MicroPort NeuroTech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.